Related Experiment Videos
Gemcitabine: a cytidine analogue active against solid tumors
1Department of Pharmacy Services, University of Michigan Medical Center, (UMMC), Ann Arbor, USA.
Summary
Gemcitabine, a deoxycytidine-analogue antimetabolite, effectively palliates symptoms in advanced pancreatic cancer patients. Further research is needed to establish its role in treating non-small-cell lung, ovarian, and breast cancers.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Gemcitabine is a deoxycytidine analogue antimetabolite used in cancer therapy.
- It functions by inhibiting DNA synthesis and repair mechanisms within cancer cells.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of gemcitabine.
- To evaluate gemcitabine's role in treating various solid tumors, particularly pancreatic cancer.
Main Methods:
- Review of existing literature on gemcitabine's properties and clinical applications.
- Analysis of clinical trial data regarding efficacy, safety, and dosing in different cancer types.
Main Results:
- Gemcitabine demonstrated efficacy in reducing pain and improving function in advanced pancreatic cancer.
- The drug showed activity against non-small-cell lung cancer (in combination), ovarian, and breast cancers.
- Common adverse effects include myelosuppression, flu-like symptoms, nausea, and vomiting.
Conclusions:
- Gemcitabine is FDA-approved for advanced pancreatic cancer, offering palliative benefits.
- Its role in other solid tumors requires further investigation.
- Optimal dosing strategies are established for pancreatic cancer treatment.